Skip to main content
. 2021 Nov 24;12:760181. doi: 10.3389/fpsyt.2021.760181

Table 5.

Summary of putative clinical impact of APP treatment involving partial agonists.

Issue Type Putative clinical impact (target/s)
Positive symptoms Desired Improvement (partial D2)
Negative symptoms Desired Improvement (partial D3)
Hyperprolactinaemia (RIS, HAL, PAL) AE Attenuation (partial D2)
Weight/metabolic (e.g., OLA, CLZ) AE Improvement (interaction partial D2 vs. H1/5-HT2C?)
Sedation (e.g., OLA, RIS) AE Improvement (interaction partial D2 vs. H1?)